论文部分内容阅读
Accompanying the current epidemics of metabolic syndrome (MS) and obesity caused by westeization of lifestyles, the incidences of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been increasing worldwide over the last few decades (1). Now, NAFLD has a global prevalence estimated at 25%of the world population, with some geographical; the highest prevalences are in the South America and Middle East. Namely, NAFLD has become recognized as the most common liver disease worldwide (2).